Variable/Field Name,Matrix Group Name,Minimal (Required),Mandatory,Section,Field Type,Label,Code,Default,Validation Type,Validation Min,Validation Max,Field Note,Branching Logic,FHIR Resource,FHIR - Question Coding,FHIR - Answer Coding,Note
record_id,,Yes,Yes,,text,Patient ID,,,,,,,,Patient,,,
sex,,Yes,Yes,Observation,dropdown,Sex,0; male | 1; female,1,,,,MINIMAL,,Observation,"{"system": "http://loinc.org","code": "76689-9","display": "Sex assigned at birth"}","{0: {"system":"http://loinc.org","code":"LA2-8","display":"Male"}, 1: {"system":"http://loinc.org","code":"LA3-6","display":"Female"}}",
deceased,,No,No,Patient,dropdown,Vital status (deceased),0; alive | 1; deceased,,,,,RECOMMENDED,,Patient,"["deceasedBoolean"]","{0:"True",1:"False"}",
onsetage,,Yes,Yes,Condition,text,Age at diagnosis,,,integer,0,110,MINIMAL,,Condition,"["onsetage" ]","{"value":onsetage,"unit":"years","code":"a","system":"http://unitsofmeasure.org"}",
bcstproxy,,No,Yes,Condition,dropdown,Breast cancer subtype 'by-proxy',0; Basal-like/Triple negative | 1; Luminal A | 2; Luminal B- HER2 negative | 3; HER2 positive (enriched)/HR positive (luminal) | 4; HER2 positive(enriched)/HR negative (non-luminal),,,,,MANDATORY,,Observation,"{"system":"http://snomed.info/sct","code":"372064008+260837004","display":"Malignant neoplasm of female breast, and Subtype"}","{0:{"system":"http://snomed.info/sct","code":"706970001","display":"Triple negative malignant neoplasm of breast (disorder)"},1:[{"code":{"coding":[{"system":"http://loinc.org","code":"16112-5","display":"Estrogen receptor [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"416053008","display":"Estrogen receptor positive tumor (disorder)"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"16113-3","display":"Progesterone receptor [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"416561008","display":"Progesterone receptor positive tumor (disorder)"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"48676-1","display":"HER2 [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"431396003","display":"Human epidermal growth factor 2 negative carcinoma of breast (disorder)"}]}},{"code":{"coding":[{"system":"http://ncithesaurus-stage.nci.nih.gov","code":"C123557","display":"Ki67 Measurement"}]},valueCodeableConcept:{"coding":[{"system":"http://ncithesaurus-stage.nci.nih.gov","code":"C162076","display":"MKI67 Negative"}]}}],2:[{"code":{"coding":[{"system":"http://loinc.org","code":"16112-5","display":"Estrogen receptor [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"416053008","display":"Estrogen receptor positive tumor (disorder)"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"16113-3","display":"Progesterone receptor [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"416561008","display":"Progesterone receptor positive tumor (disorder)"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"48676-1","display":"HER2 [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"431396003","display":"Human epidermal growth factor 2 negative carcinoma of breast (disorder)"}]}},{"code":{"coding":[{"system":"http://ncithesaurus-stage.nci.nih.gov","code":"C123557","display":"Ki67 Measurement"}]},valueCodeableConcept:{"coding":[{"system":"http://ncithesaurus-stage.nci.nih.gov","code":"C146686","display":"MKI67 Positive"}]}}],3:[{"code":{"coding":[{"system":"http://loinc.org","code":"16112-5","display":"Estrogen receptor [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"416053008","display":"Estrogen receptor positive tumor (disorder)"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"16113-3","display":"Progesterone receptor [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"416561008","display":"Progesterone receptor positive tumor (disorder)"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"48676-1","display":"HER2 [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"427685000","display":"Human epidermal growth factor 2 positive carcinoma of breast (disorder)"}]}},{"code":{"coding":[{"system":"http://ncithesaurus-stage.nci.nih.gov","code":"C123557","display":"Ki67 Measurement"}]},valueCodeableConcept:{"coding":[{"system":"http://ncithesaurus-stage.nci.nih.gov","code":"C146686","display":"MKI67 Positive"}]}}],4:[{"code":{"coding":[{"system":"http://loinc.org","code":"16112-5","display":"Estrogen receptor [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"441117001","display":"Estrogen receptor negative neoplasm (disorder)"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"16113-3","display":"Progesterone receptor [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"441118006","display":"Progesterone receptor negative neoplasm (disorder)"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"48676-1","display":"HER2 [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"427685000","display":"Human epidermal growth factor 2 positive carcinoma of breast (disorder)"}]}}]}",
bcst_pam50,,No,No,Condition,dropdown,Breast Cancer Molecular subtype (PAM50),0; Basal-like/Triple negative | 1; Luminal A | 2; Luminal B- HER2 negative | 3; HER2 positive (enriched)/HR positive (luminal) | 4; HER2 positive(enriched)/HR negative (non-luminal),,,,,RECOMMENDED,,Observation,"{"system":"http://snomed.info/sct","code":"372064008+260837004","display":"Malignant neoplasm of female breast, and Subtype"}","{0:{"system":"http://snomed.info/sct","code":"706970001","display":"Triple negative malignant neoplasm of breast (disorder)"},1:[{"code":{"coding":[{"system":"http://loinc.org","code":"16112-5","display":"Estrogen receptor [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"416053008","display":"Estrogen receptor positive tumor (disorder)"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"16113-3","display":"Progesterone receptor [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"416561008","display":"Progesterone receptor positive tumor (disorder)"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"48676-1","display":"HER2 [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"431396003","display":"Human epidermal growth factor 2 negative carcinoma of breast (disorder)"}]}},{"code":{"coding":[{"system":"http://ncithesaurus-stage.nci.nih.gov","code":"C123557","display":"Ki67 Measurement"}]},valueCodeableConcept:{"coding":[{"system":"http://ncithesaurus-stage.nci.nih.gov","code":"C162076","display":"MKI67 Negative"}]}}],2:[{"code":{"coding":[{"system":"http://loinc.org","code":"16112-5","display":"Estrogen receptor [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"416053008","display":"Estrogen receptor positive tumor (disorder)"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"16113-3","display":"Progesterone receptor [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"416561008","display":"Progesterone receptor positive tumor (disorder)"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"48676-1","display":"HER2 [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"431396003","display":"Human epidermal growth factor 2 negative carcinoma of breast (disorder)"}]}},{"code":{"coding":[{"system":"http://ncithesaurus-stage.nci.nih.gov","code":"C123557","display":"Ki67 Measurement"}]},valueCodeableConcept:{"coding":[{"system":"http://ncithesaurus-stage.nci.nih.gov","code":"C146686","display":"MKI67 Positive"}]}}],3:[{"code":{"coding":[{"system":"http://loinc.org","code":"16112-5","display":"Estrogen receptor [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"416053008","display":"Estrogen receptor positive tumor (disorder)"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"16113-3","display":"Progesterone receptor [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"416561008","display":"Progesterone receptor positive tumor (disorder)"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"48676-1","display":"HER2 [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"427685000","display":"Human epidermal growth factor 2 positive carcinoma of breast (disorder)"}]}},{"code":{"coding":[{"system":"http://ncithesaurus-stage.nci.nih.gov","code":"C123557","display":"Ki67 Measurement"}]},valueCodeableConcept:{"coding":[{"system":"http://ncithesaurus-stage.nci.nih.gov","code":"C146686","display":"MKI67 Positive"}]}}],4:[{"code":{"coding":[{"system":"http://loinc.org","code":"16112-5","display":"Estrogen receptor [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"441117001","display":"Estrogen receptor negative neoplasm (disorder)"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"16113-3","display":"Progesterone receptor [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"441118006","display":"Progesterone receptor negative neoplasm (disorder)"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"48676-1","display":"HER2 [Interpretation] in Tissue"}]},valueCodeableConcept:{"coding":[{"system":"http://snomed.info/sct","code":"427685000","display":"Human epidermal growth factor 2 positive carcinoma of breast (disorder)"}]}}]}","["method"]={"coding":{"system":"http://ncithesaurus-stage.nci.nih.gov","code":"C120494","display":"PAM50"}} "
histopat,,Yes,Yes,Condition,dropdown,Histological Type of tumour,0; Only ductal cancer | 1; Both ductal and lobular cancer | 2; Ductal and other types than lobular cancer | 3; Only lobular cancer | 4; Other invasive cancer | 5; DCIS | 6; LCIS | 7; DCIS and LCIS | 8; Other cancer in situ,,,,,MINIMAL,,Condition,"["code":{"coding":histopat}","{0:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8500/3","display":"DUCT CARCINOMA/ Invasive carcinoma of no special type"},1:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8522/3","display":"LOBULAR AND OTHER DUCTAL CA. / Infiltrating duct and lobular carcinoma"},2:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8523/3","display":"LOBULAR AND OTHER DUCTAL CA. / Infiltr. duct mixed with other types of carcinoma"},3:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8520/3","display":"LOBULAR AND OTHER DUCTAL CA. / Lobular carcinoma, NOS"},4:{"system":"http://snomed.info/sct","code":"713609000:410657003=74964007","display":"Invasive carcinoma of breast where Type - attribute = Other"},5:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8500/2","display":"DUCT CARCINOMA/ Intraductal carcinoma, noninfiltrating, NOS"},6:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8520/2","display":"LOBULAR AND OTHER DUCTAL CA. / Lobular carcinoma insitu"},7:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8522/2","display":"LOBULAR AND OTHER DUCTAL CA. / Intraductal and lobular in situ carcinoma"},8:{"system":"http://snomed.info/sct","code":"1187138006","display":"Carcinoma in situ (morphologic abnormality)"}}",
histopat_2,,No,No,Condition,dropdown,Additional Histological Type of tumour (only if needed),0; Only ductal cancer | 1; Both ductal and lobular cancer | 2; Ductal and other types than lobular cancer | 3; Only lobular cancer | 4; Other invasive cancer | 5; DCIS | 6; LCIS | 7; DCIS and LCIS | 8; Other cancer in situ,,,,,RECOMMENDED,"[histopat] <> ",Condition,"["code":{"coding":histopat_2}","{0:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8500/3","display":"DUCT CARCINOMA/ Invasive carcinoma of no special type"},1:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8522/3","display":"LOBULAR AND OTHER DUCTAL CA. / Infiltrating duct and lobular carcinoma"},2:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8523/3","display":"LOBULAR AND OTHER DUCTAL CA. / Infiltr. duct mixed with other types of carcinoma"},3:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8520/3","display":"LOBULAR AND OTHER DUCTAL CA. / Lobular carcinoma, NOS"},4:{"system":"http://snomed.info/sct","code":"713609000:410657003=74964007","display":"Invasive carcinoma of breast where Type - attribute = Other"},5:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8500/2","display":"DUCT CARCINOMA/ Intraductal carcinoma, noninfiltrating, NOS"},6:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8520/2","display":"LOBULAR AND OTHER DUCTAL CA. / Lobular carcinoma insitu"},7:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8522/2","display":"LOBULAR AND OTHER DUCTAL CA. / Intraductal and lobular in situ carcinoma"},8:{"system":"http://snomed.info/sct","code":"1187138006","display":"Carcinoma in situ (morphologic abnormality)"}}",
histopat_3,,No,No,Condition,dropdown,Additional Histological Type of tumour (only if needed),0; Only ductal cancer | 1; Both ductal and lobular cancer | 2; Ductal and other types than lobular cancer | 3; Only lobular cancer | 4; Other invasive cancer | 5; DCIS | 6; LCIS | 7; DCIS and LCIS | 8; Other cancer in situ,,,,,RECOMMENDED,"[histopat_2] <> ",Condition,"["code":{"coding":histopat_3}","{0:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8500/3","display":"DUCT CARCINOMA/ Invasive carcinoma of no special type"},1:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8522/3","display":"LOBULAR AND OTHER DUCTAL CA. / Infiltrating duct and lobular carcinoma"},2:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8523/3","display":"LOBULAR AND OTHER DUCTAL CA. / Infiltr. duct mixed with other types of carcinoma"},3:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8520/3","display":"LOBULAR AND OTHER DUCTAL CA. / Lobular carcinoma, NOS"},4:{"system":"http://snomed.info/sct","code":"713609000:410657003=74964007","display":"Invasive carcinoma of breast where Type - attribute = Other"},5:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8500/2","display":"DUCT CARCINOMA/ Intraductal carcinoma, noninfiltrating, NOS"},6:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8520/2","display":"LOBULAR AND OTHER DUCTAL CA. / Lobular carcinoma insitu"},7:{"system":"http://terminology.hl7.org/CodeSystem/icd-o-3","code":"8522/2","display":"LOBULAR AND OTHER DUCTAL CA. / Intraductal and lobular in situ carcinoma"},8:{"system":"http://snomed.info/sct","code":"1187138006","display":"Carcinoma in situ (morphologic abnormality)"}}",
recurrence,,No,No,Condition,dropdown,Recurrence,0; yes | 1; no,,,,,RECOMMENDED,,Condition,"["clinicalStatus"]","{0:{"system":"http://terminology.hl7.org/CodeSystem/condition-clinical","code":"recurrence"},1:{"system":"http://terminology.hl7.org/CodeSystem/condition-clinical","code":"inactive"}}",
dfs,,No,No,Observation,text,Disease free survival: relapse interval (months),,,integer,,,RECOMMENDED - From surgery until recurrence/relapse,,Observation,"{"system":"http://snomed.info/sct","code":"445150007","display":"Surviving free of recurrence of neoplastic disease (finding)"}","{"value":dfs,"unit":"month","system":"http://unitsofmeasure.org","code":"mo"}",
os,,No,No,Observation,text,Overall survival: time from diagnosis to death (months),,,integer,,,RECOMMENDED,,Observation,"{"system":"http://snomed.info/sct","code":"445320007","display":"Survival time (observable entity)"}","{"value":os,"unit":"month","system":"http://unitsofmeasure.org","code":"mo"}",
menop,,No,Yes,Observation,dropdown,Menopausal status,0; premenopause | 1; postmenopause,,,,,MANDATORY,,Observation,"{"system":"http://snomed.info/sct","code":"161712005","display":"Menopause, function (observable entity)"}","{0:{"system":"http://snomed.info/sct","code":"289904000","display":"Menopause absent (finding)"},1:{"system":"http://snomed.info/sct","code":"289903006","display":"Menopause present (finding)"}}",
n_preg,,No,No,Observation,text,Number of pregnancies,,,integer,,,RECOMMENDED,,Observation,"{"system":"http://snomed.info/sct","code":"161732006","display":"Gravida (observable entity)"}","{"value":n_preg,"unit":"Unit","system":"http://unitsofmeasure.org","code":"U"}",
lactation,,No,No,Observation,dropdown,Breastfeeding,0; yes | 1; no | 2; unknown,2,,,,RECOMMENDED,,Observation,"{"system":"http://snomed.info/sct","code":"413712001","display":"Breastfeeding (mother)"}","{0:{"system":"http://snomed.info/sct","code":"373066001","display":"Yes"},1:{"system":"http://snomed.info/sct","code":"260415000","display":"Not detected"},2:{"system":"http://snomed.info/sct","code":"261665006","display":"Unknown"}}",
lactation_dur,,No,No,Observation,text,Length of breastfeeding (months),,,integer,,,RECOMMENDED,"[lactation] = "0",Observation,"["effectivePeriod"]","{"start":1970-01-01T00:00:00+00:00,end:"start"+lactation_dur}",effectivePeriod variable has anonymized dates. The duration is the difference in time between both dates.
famhisto_b,,No,No,Observation,dropdown,Family history - Breast cancer,0; none | 1; first degree | 2; second degree | 3; unknown,,,,,RECOMMENDED,,Observation,"{"system":"http://snomed.info/sct","code":"416471007:64572001=372064008","display":"Family history of clinical finding where Disease = Malignant neoplasm of female breast"}","{0:{"system":"http://snomed.info/sct","code":"260413007","display":"None (qualifier value)"},1:{"system":"http://snomed.info/sct","code":"125678001","display":"First degree blood relative"},2:{"system":"http://snomed.info/sct","code":"699110007","display":"Second degree blood relative"},3:{"system":"http://snomed.info/sct","code":"261665006","display":"Unknown"}}",
famhisto_o,,No,No,Observation,dropdown,Family history - Ovarian cancer,0; none | 1; first degree | 2; second degree | 3; unknown,,,,,RECOMMENDED,,Observation,"{"system":"http://snomed.info/sct","code":"416471007:64572001=363443007","display":"Family history of clinical finding where Disease = Malignant tumour of ovary"}","{0:{"system":"http://snomed.info/sct","code":"260413007","display":"None (qualifier value)"},1:{"system":"http://snomed.info/sct","code":"125678001","display":"First degree blood relative"},2:{"system":"http://snomed.info/sct","code":"699110007","display":"Second degree blood relative"},3:{"system":"http://snomed.info/sct","code":"261665006","display":"Unknown"}}",
hormtherapy,,No,No,Observation,dropdown,Use of hormonal replacement therapy,0; yes | 1; no | 2; unknown,2,,,,RECOMMENDED,,Observation,"{"system":"http://snomed.info/sct","code":"266717002","display":"Hormone replacement therapy (procedure)"}","{0:{"system":"http://snomed.info/sct","code":"373066001","display":"Yes"},1:{"system":"http://snomed.info/sct","code":"260415000","display":"Not detected"},2:{"system":"http://snomed.info/sct","code":"261665006","display":"Unknown"}}",
hormtherapy_dur,,No,No,Observation,text,Use of hormonal replacement duration (months),,,integer,,,RECOMMENDED,"[hormtherapy] = "0",Observation,"["effectivePeriod"]","{"start":1970-01-01T00:00:00+00:00,end:"start"+hormtherapy_dur}",effectivePeriod variable has anonymized dates. The duration is the difference in time between both dates.
laterality,,No,No,Observation,dropdown,Laterality of the lesion,0; Left | 2; Right,,,,,RECOMMENDED,,Observation,"["bodySite"]","{0:{"system":"http://snomed.info/sct","code":"80248007","display":"Left breast structure (body structure)"},1:{"system":"http://snomed.info/sct","code":"73056007","display":"Right breast structure (body structure)"}}",
tnm_ct,ctnm (start),Yes,Yes,Biopsy,dropdown,Clinical t category (cT),0; cTX | 1; cT0 | 2; cTis | 3; cTis(DCIS) | 4; cTis(Paget) | 5; cT1 | 6; cT1mi | 7; cT1a | 8; cT1b | 9; cT1c | 10; cT2 | 11; cT3 | 12; cT4 | 13; cT4a | 14; cT4b | 15; cT4c | 16; cT4d,,,,,MINIMAL,,Observation,"{"system":"http://snomed.info/sct","code":"1222585009","display":"American Joint Committee on Cancer clinical T category allowable value (qualifier value)"}","{0:{"system":"http://snomed.info/sct","code":"1222604002","display":"cTX"},1:{"system":"http://snomed.info/sct","code":"1228882005","display":"cT0"},2:{"system":"http://snomed.info/sct","code":"1228884006","display":"cTis"},3:{"system":"http://snomed.info/sct","code":"1228885007","display":"cTis(DCIS)"},4:{"system":"http://snomed.info/sct","code":"1228888009","display":"cTis(Paget)"},5:{"system":"http://snomed.info/sct","code":"1228889001","display":"cT1"},6:{"system":"http://snomed.info/sct","code":"1228892002","display":"cT1a"},7:{"system":"http://snomed.info/sct","code":"1228895000","display":"cT1b"},8:{"system":"http://snomed.info/sct","code":"1228899006","display":"cT1c"},9:{"system":"http://snomed.info/sct","code":"1228891009","display":"cT1mi"},10:{"system":"http://snomed.info/sct","code":"1228929004","display":"cT2"},11:{"system":"http://snomed.info/sct","code":"1228938002","display":"cT3"},12:{"system":"http://snomed.info/sct","code":"1228944003","display":"cT4"},13:{"system":"http://snomed.info/sct","code":"1228945002","display":"cT4a"},14:{"system":"http://snomed.info/sct","code":"1228946001","display":"cT4b"},15:{"system":"http://snomed.info/sct","code":"1228947005","display":"cT4c"},16:{"system":"http://snomed.info/sct","code":"1228948000","display":"cT4d"}}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"86273004","display":"Biopsy (procedure)"}}"
tnm_cn,ctnm (end),No,Yes,Biopsy,dropdown,Clinical n category (cN),0; cNX | 1; cN0 | 2; cN1 | 3; cN1mi | 4; cN2 | 5; cN2a | 6; cN2b | 7; cN3 | 8; cN3a | 9; cN3b | 10; cN3c,,,,,MANDATORY,,Observation,"{"system":"http://snomed.info/sct","code":"1222588006","display":"American Joint Committee on Cancer clinical N category allowable value (qualifier value)"}","{0:{"system":"http://snomed.info/sct","code":"1229966003","display":"cNX"},1:{"system":"http://snomed.info/sct","code":"1229967007","display":"cN0"},2:{"system":"http://snomed.info/sct","code":"1229973008","display":"cN1"},3:{"system":"http://snomed.info/sct","code":"1229974002","display":"cN1mi"},4:{"system":"http://snomed.info/sct","code":"1229978004","display":"cN2"},5:{"system":"http://snomed.info/sct","code":"1229981009","display":"cN2a"},6:{"system":"http://snomed.info/sct","code":"1229982002","display":"cN2b"},7:{"system":"http://snomed.info/sct","code":"1229984001","display":"cN3"},8:{"system":"http://snomed.info/sct","code":"1229985000","display":"cN3a"},9:{"system":"http://snomed.info/sct","code":"1229986004","display":"cN3b"},10:{"system":"http://snomed.info/sct","code":"1229987008","display":"cN3c"}}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"86273004","display":"Biopsy (procedure)"}}"
grade,,No,Yes,Biopsy,dropdown,Grading of invasive tumours,0; G1 | 1; G2 | 2; G3 | 3; Gx,,,,,MANDATORY,,Observation,"{"system":"http://snomed.info/sct","code":"258244004","display":"Tumor histopathological grade status values (tumor staging)"}","{0:{"system":"http://snomed.info/sct","code":"1228845001","display":"American Joint Committee on Cancer grade GX (qualifier value)"},1:{"system":"http://snomed.info/sct","code":"1228848004","display":"American Joint Committee on Cancer grade G1 (qualifier value)"},2:{"system":"http://snomed.info/sct","code":"1228850007","display":"American Joint Committee on Cancer grade G2 (qualifier value)"},3:{"system":"http://snomed.info/sct","code":"1228851006","display":"American Joint Committee on Cancer grade G3 (qualifier value)"}}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"86273004","display":"Biopsy (procedure)"}}"
n_lymphnodes,,No,Yes,Biopsy,text,Total number of lymph nodes examined,,,integer,,,MANDATORY,,Observation,"{"system":"http://snomed.info/sct","code":"444025001","display":"Number of lymph nodes examined by microscopy in excised specimen (observable entity)"}","{"value":n_lymphnodes,"unit":"Unit","system":"http://unitsofmeasure.org","code":"U"}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"86273004","display":"Biopsy (procedure)"}}"
er,,Yes (([histopat]<>'' AND [histopat]<5) OR ([histopat_2]<>'' AND [histopat_2]<5) OR ([histopat_3]<>'' AND [histopat_3]<5)),Yes (([histopat]<>'' AND [histopat]<5) OR ([histopat_2]<>'' AND [histopat_2]<5) OR ([histopat_3]<>'' AND [histopat_3]<5)),Biopsy,text,ER percent positive,,,number,,,MINIMAL - %,,Observation,"{"system":"http://loinc.org","code":"85329-1","display":"Cells.estrogen receptor/100 cells in Breast cancer specimen by Immune stain"}","{"value":er,"unit":"percent","system":"http://unitsofmeasure.org","code":"%"}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"86273004","display":"Biopsy (procedure)"}}"
pr,,Yes (([histopat]<>'' AND [histopat]<5) OR ([histopat_2]<>'' AND [histopat_2]<5) OR ([histopat_3]<>'' AND [histopat_3]<5)),Yes (([histopat]<>'' AND [histopat]<5) OR ([histopat_2]<>'' AND [histopat_2]<5) OR ([histopat_3]<>'' AND [histopat_3]<5)),Biopsy,text,PR percent positive,,,number,,,MINIMAL - %,,Observation,"{"system":"http://loinc.org","code":"85325-9","display":"Cells.progesterone receptor/100 cells in Breast cancer specimen by Immune stain"}","{"value":pr,"unit":"percent","system":"http://unitsofmeasure.org","code":"%"}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"86273004","display":"Biopsy (procedure)"}}"
her2ihc,,Yes (([histopat]<>'' AND [histopat]<5) OR ([histopat_2]<>'' AND [histopat_2]<5) OR ([histopat_3]<>'' AND [histopat_3]<5)),Yes (([histopat]<>'' AND [histopat]<5) OR ([histopat_2]<>'' AND [histopat_2]<5) OR ([histopat_3]<>'' AND [histopat_3]<5)),Biopsy,dropdown,HER2 IHC Status,0; 0+ | 1; 1+ | 2; 2+ | 3; 3+,,,,,MINIMAL,,Observation,"{"system":"http://loinc.org","code":"85319-2","display":"HER2 [Presence] in Breast cancer specimen by Immune stain"}","{0:{"system":"http://loinc.org","code":"LA6111-4","display":"0"},1:{"system":"http://loinc.org","code":"LA11841-6","display":"1+"},2:{"system":"http://loinc.org","code":"LA11842-4","display":"2+"},3:{"system":"http://loinc.org","code":"LA11843-2","display":"3+"}}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"86273004","display":"Biopsy (procedure)"}}"
ki67,,Yes (([histopat]<>'' AND [histopat]<5) OR ([histopat_2]<>'' AND [histopat_2]<5) OR ([histopat_3]<>'' AND [histopat_3]<5)),Yes (([histopat]<>'' AND [histopat]<5) OR ([histopat_2]<>'' AND [histopat_2]<5) OR ([histopat_3]<>'' AND [histopat_3]<5)),Biopsy,text,Ki67 percent positive,,,number,,,MINIMAL - %,,Observation,"{"system":"http://loinc.org","code":"85330-9","display":"Cells.Ki-67 nuclear Ag/100 cells in Breast cancer specimen by Immune stain"}","{"value":ki67,"unit":"percent","system":"http://unitsofmeasure.org","code":"%"}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"86273004","display":"Biopsy (procedure)"}}"
her2fish,,Yes ([her2ihc] = '2'),Yes ([her2ihc] = '2'),Biopsy,dropdown,HER2 FISH Status,0; positive | 1; negative,,,,,MINIMAL,[her2ihc] = '2',Observation,"{"system":"http://loinc.org","code":"85318-4","display":"ERBB2 gene duplication [Presence] in Breast cancer specimen by FISH"}","{0:{"system":"http://snomed.info/sct","code":"10828004","display":"Positive"},1:{"system":"http://snomed.info/sct","code":"260385009","display":"Negative"},2:{"system":"http://snomed.info/sct","code":"261665006","display":"Unknown"}}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"86273004","display":"Biopsy (procedure)"}}"
tnm_ypt,ptnm (start),Yes,Yes,Observation - Definitive Anatomical Pathology,dropdown,Posttherapy t category (ypT),0; ypTX | 1;  ypT0 | 2;  ypTis | 3; ypTis(DCIS) | 4; ypTis(Paget) | 5; ypT1 | 6; ypT1mi | 7; ypT1a | 8; ypT1b | 9; ypT1c | 10; ypT2 | 11; ypT3 | 12; ypT4 | 13; ypT4a | 14; ypT4b | 15; ypT4c | 16; ypT4d,,,,,MINIMAL,,Observation,"{"system":"http://snomed.info/sct","code":"1222595002","display":"American Joint Committee on Cancer ypT category allowable value (qualifier value)"}","{0:{"system":"http://snomed.info/sct","code":"1228862006","display":"ypTx"},1:{"system":"http://snomed.info/sct","code":"1228863001","display":"ypT0"},2:{"system":"http://snomed.info/sct","code":"1228865008","display":"ypTis"},3:{"system":"http://snomed.info/sct","code":"1228866009","display":"ypTis(DCIS)"},4:{"system":"http://snomed.info/sct","code":"1228868005","display":"ypTis(Paget)"},5:{"system":"http://snomed.info/sct","code":"1228869002","display":"ypT1"},6:{"system":"http://snomed.info/sct","code":"1228870001","display":"ypT1mi"},7:{"system":"http://snomed.info/sct","code":"1228872009","display":"ypT1a"},8:{"system":"http://snomed.info/sct","code":"1228897008","display":"ypT1b"},9:{"system":"http://snomed.info/sct","code":"1228905006","display":"ypT1c"},10:{"system":"http://snomed.info/sct","code":"1228910005","display":"ypT2"},11:{"system":"http://snomed.info/sct","code":"1228917008","display":"ypT3"},12:{"system":"http://snomed.info/sct","code":"1228922008","display":"ypT4"},13:{"system":"http://snomed.info/sct","code":"1228923003","display":"ypT4a"},14:{"system":"http://snomed.info/sct","code":"1228924009","display":"ypT4b"},15:{"system":"http://snomed.info/sct","code":"1228925005","display":"ypT4c"},16:{"system":"http://snomed.info/sct","code":"1228926006","display":"ypT4d"}}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"1255732006","display":"Anatomic pathology (qualifier value)"}}"
tnm_ypn,ptnm,Yes,Yes,Observation - Definitive Anatomical Pathology,dropdown,Pathological n category (ypN),0; ypNX | 1; ypN0 | 2; ypN1 | 3; ypN1mi | 4; ypN1a | 5; ypN1b | 6; ypN1c | 7; ypN2 | 8; ypN2a | 9; ypN2b | 10; ypN3 | 11; ypN3a | 12; ypN3b | 13; ypN3c,,,,,MINIMAL,,Observation,"{"system":"http://snomed.info/sct","code":"1222596001","display":"American Joint Committee on Cancer ypN category allowable value (qualifier value)"}","{0:{"system":"http://snomed.info/sct","code":"1229877005","display":"ypNX"},1:{"system":"http://snomed.info/sct","code":"1229878000","display":"ypN0"},2:{"system":"http://snomed.info/sct","code":"1229884002","display":"ypN1"},3:{"system":"http://snomed.info/sct","code":"1229885001","display":"ypN1mi"},4:{"system":"http://snomed.info/sct","code":"1229887009","display":"ypN1a"},5:{"system":"http://snomed.info/sct","code":"1229889007","display":"ypN1b"},6:{"system":"http://snomed.info/sct","code":"1229890003","display":"ypN1c"},7:{"system":"http://snomed.info/sct","code":"1229892006","display":"ypN2"},8:{"system":"http://snomed.info/sct","code":"1229893001","display":"ypN2a"},9:{"system":"http://snomed.info/sct","code":"1229896009","display":"ypN2b"},10:{"system":"http://snomed.info/sct","code":"1229897000","display":"ypN3"},11:{"system":"http://snomed.info/sct","code":"1229898005","display":"ypN3a"},12:{"system":"http://snomed.info/sct","code":"1229899002","display":"ypN3b"},13:{"system":"http://snomed.info/sct","code":"1229900007","display":"ypN3c"}}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"1255732006","display":"Anatomic pathology (qualifier value)"}}"
tnm_ypm,ptnm (end),Yes,Yes,Observation - Definitive Anatomical Pathology,dropdown,Posttherapy t category (ypM),0; pM0 | 1; pM1 | 2; pM1a | 3; pM1b | 4; pM1c | 5; pM1d,,,,,MINIMAL,,Observation,"{"system":"http://snomed.info/sct","code":"1222591006","display":"American Joint Committee on Cancer pathological M category allowable value (qualifier value)"}","{0:{"system":"http://ncithesaurus-stage.nci.nih.gov","code":"C48740","display":"pM0 TNM Finding"},1:{"system":"http://snomed.info/sct","code":"1229916009","display":"pM1"},2:{"system":"http://snomed.info/sct","code":"1229917000","display":"pM1a"},3:{"system":"http://snomed.info/sct","code":"1229920008","display":"pM1b"},4:{"system":"http://snomed.info/sct","code":"1229923005","display":"pM1c"},5:{"system":"http://snomed.info/sct","code":"1229926002","display":"pM1d"}}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"1255732006","display":"Anatomic pathology (qualifier value)"}}"
grade_ap,,No,Yes,Observation - Definitive Anatomical Pathology,dropdown,Grading of invasive tumours,0; G1 | 1; G2 | 2; G3 | 3; Gx,,,,,MANDATORY,,Observation,"{"system":"http://snomed.info/sct","code":"258244004","display":"Tumor histopathological grade status values (tumor staging)"}","{0:{"system":"http://snomed.info/sct","code":"1228845001","display":"American Joint Committee on Cancer grade GX (qualifier value)"},1:{"system":"http://snomed.info/sct","code":"1228848004","display":"American Joint Committee on Cancer grade G1 (qualifier value)"},2:{"system":"http://snomed.info/sct","code":"1228850007","display":"American Joint Committee on Cancer grade G2 (qualifier value)"},3:{"system":"http://snomed.info/sct","code":"1228851006","display":"American Joint Committee on Cancer grade G3 (qualifier value)"}}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"1255732006","display":"Anatomic pathology (qualifier value)"}}"
lymp_inv,,No,Yes,Observation - Definitive Anatomical Pathology,dropdown,Lymphovascular invasion,0; present | 1; absent | 2; unknown,,,,,MANDATORY,,Observation,"{"system":"http://snomed.info/sct","code":"371512006","display":"Presence of direct invasion by primary malignant neoplasm to lymphatic vessel and/or small blood vessel (observable entity)"}",,"["method"] = {"coding":{"system":"http://snomed.info/sct","code":"1255732006","display":"Anatomic pathology (qualifier value)"}}"
ln_pos,,No,Yes,Observation - Definitive Anatomical Pathology,text,Lymph nodes positive,,,integer,,,MANDATORY,"[lymp_inv] = "0",Observation,"{"system":"http://snomed.info/sct","code":"443527007","display":"Number of lymph nodes containing metastatic neoplasm in excised specimen (observable entity)"}",,"["method"] = {"coding":{"system":"http://snomed.info/sct","code":"1255732006","display":"Anatomic pathology (qualifier value)"}}"
trg,,No,Yes,Observation - Definitive Anatomical Pathology,dropdown,Miller and Payne's Tumor Regression Grade,0; G1 | 1; G2 | 2; G3 | 3; G4 | 4; G5,,,,,MANDATORY,,Observation,"{"system":"http://ncithesaurus-stage.nci.nih.gov","code":"C63611","display":"Miller and Payne Classification"}","{0:{"system":"http://snomed.info/sct","code":"1157337001","display":"Grade 1 on a scale of 1 to 5 (qualifier value)"},1:{"system":"http://snomed.info/sct","code":"1157338006","display":"Grade 2 on a scale of 1 to 5 (qualifier value)"},2:{"system":"http://snomed.info/sct","code":"1157339003","display":"Grade 3 on a scale of 1 to 5 (qualifier value)"},3:{"system":"http://snomed.info/sct","code":"1157340001","display":"Grade 4 on a scale of 1 to 5 (qualifier value)"},4:{"system":"http://snomed.info/sct","code":"1157341002","display":"Grade 5 on a scale of 1 to 5 (qualifier value)"}}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"1255732006","display":"Anatomic pathology (qualifier value)"}}"
rcb,,No,No,Observation - Definitive Anatomical Pathology,dropdown,RCB Class,0; RCB-0 | 1; RCB-I | 2; RCB-II | 3; RCB-III,,,,,RECOMMENDED,,Observation,"{"system":"http://snomed.info/sct","code":"444987009","display":"Residual cancer burden class (observable entity)"}","{0:{"system":"http://ncithesaurus-stage.nci.nih.gov","code":"C160725","display":"Residual Cancer Burden Class 0"},1:{"system":"http://ncithesaurus-stage.nci.nih.gov","code":"C160726","display":"Residual Cancer Burden Class 1"},2:{"system":"http://ncithesaurus-stage.nci.nih.gov","code":"C160727","display":"Residual Cancer Burden Class 2"},3:{"system":"http://ncithesaurus-stage.nci.nih.gov","code":"C160728","display":"Residual Cancer Burden Class 3"}}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"1255732006","display":"Anatomic pathology (qualifier value)"}}"
er_ap,,No,No,Observation - Definitive Anatomical Pathology,text,ER percent positive,,,number,,,RECOMMENDED - %,,Observation,"{"system":"http://loinc.org","code":"85329-1","display":"Cells.estrogen receptor/100 cells in Breast cancer specimen by Immune stain"}","{"value":er,"unit":"percent","system":"http://unitsofmeasure.org","code":"%"}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"1255732006","display":"Anatomic pathology (qualifier value)"}}"
pr_ap,,No,No,Observation - Definitive Anatomical Pathology,text,PR percent positive,,,number,,,RECOMMENDED - %,,Observation,"{"system":"http://loinc.org","code":"85325-9","display":"Cells.progesterone receptor/100 cells in Breast cancer specimen by Immune stain"}","{"value":pr,"unit":"percent","system":"http://unitsofmeasure.org","code":"%"}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"1255732006","display":"Anatomic pathology (qualifier value)"}}"
her2ihc_ap,,No,No,Observation - Definitive Anatomical Pathology,dropdown,HER2 IHC Status,0; 0+ | 1; 1+ | 2; 2+ | 3; 3+,,,,,RECOMMENDED,,Observation,"{"system":"http://loinc.org","code":"85319-2","display":"HER2 [Presence] in Breast cancer specimen by Immune stain"}","{0:{"system":"http://loinc.org","code":"LA6111-4","display":"0"},1:{"system":"http://loinc.org","code":"LA11841-6","display":"1+"},2:{"system":"http://loinc.org","code":"LA11842-4","display":"2+"},3:{"system":"http://loinc.org","code":"LA11843-2","display":"3+"}}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"1255732006","display":"Anatomic pathology (qualifier value)"}}"
ki67_ap,,No,No,Observation - Definitive Anatomical Pathology,text,Ki67 percent positive,,,number,,,RECOMMENDED - %,,Observation,"{"system":"http://loinc.org","code":"85319-2","display":"HER2 [Presence] in Breast cancer specimen by Immune stain"}","{0:{"system":"http://loinc.org","code":"LA6111-4","display":"0"},1:{"system":"http://loinc.org","code":"LA11841-6","display":"1+"},2:{"system":"http://loinc.org","code":"LA11842-4","display":"2+"},3:{"system":"http://loinc.org","code":"LA11843-2","display":"3+"}}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"1255732006","display":"Anatomic pathology (qualifier value)"}}"
her2fish_ap,,No,No,Observation - Definitive Anatomical Pathology,dropdown,HER2 FISH Status,0; positive | 1; negative,,,,,RECOMMENDED,[her2ihc_ap] = '2',Observation,"{"system":"http://loinc.org","code":"85330-9","display":"Cells.Ki-67 nuclear Ag/100 cells in Breast cancer specimen by Immune stain"}","{"value":her2fish_ap,"unit":"percent","system":"http://unitsofmeasure.org","code":"%"}","["method"] = {"coding":{"system":"http://snomed.info/sct","code":"1255732006","display":"Anatomic pathology (qualifier value)"}}"
chemo_drug,,Yes,Yes,Medication Administration,dropdown,Chemotherapy agent (Neoadjuvant Systemic Treatment),0; Capecitabine | 1; Carboplatin | 2; Cyclophosphamide | 3; Docetaxel | 4; Doxorubicin | 5; Doxorubicin liposomal | 6; Epirubicin | 7; Eribulin | 8; Fluorouracil | 9; Gemcitabine | 10; Methotrexate | 11; Nab paclitaxel | 12; Paclitaxel | 13; Sacituzumab govitecán | 14; Vinorelbin | 15; Lapatinib | 16; Pertuzumab | 17; TDM1 | 18; Trastuzumab | 19; Trastuzumab deruxtecán | 20; Tucatinib | 21; Anastrozole | 22; Exemestane | 23; Letrozole | 24; Tamoxifem | 25; Atezolizumab | 26; Durvalumab | 27; Pembrolizumab | 28; Abemaciclib | 29; Palbociclib | 30; Ribociclib | 31; Abraxane | 32; Adriamycin | 33; Bevacizumab | 34; Taxotere | 35; Tremelimumab | 36; Xentuzumab,,,,,MINIMAL,,MedicationAdministration,"medicationCodeableConcept":{"coding":chemo_drug}","{0: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"194000","display":"Capecitabine"},1: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"40048","display":"Carboplatin"},2: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"3002","display":"Cyclophosphamide"},3: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"72962","display":"Docetaxel"},4: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"3639","display":"Doxorubicin"},5: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"214525","display":"Doxorubicin liposomal"},6: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"3995","display":"Epirubicin"},7: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1045453","display":"Eribulin"},8: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"4492","display":"Fluorouracil"},9: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"12574","display":"Gemcitabine"},10: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"6851","display":"Methotrexate"},11: {"system":"http://snomed.info/sct","code":"426653008","display":"Nab paclitaxel"},12: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"56946","display":"Paclitaxel"},13: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"2360232","display":"Sacituzumab govitecan"},14: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"39541","display":"Vinorelbin"},15: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"480167","display":"Lapatinib"},16: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1298944","display":"Pertuzumab"},17: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1371041","display":"TDM1"},18: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"224905","display":"Trastuzumab"},19: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"2267582","display":"Trastuzumab deruxtecan"},20: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"2361285","display":"Tucatinib"},21: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"84857","display":"Anastrozole"},22: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"258494","display":"Exemestane"},23: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"72965","display":"Letrozole"},24: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"10324","display":"Tamoxifem"},25: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1792776","display":"Atezolizumab"},26: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1919503","display":"Durvalumab"},27: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1547545","display":"Pembrolizumab"},28: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1946825","display":"Abemaciclib"},29: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1601374","display":"Palbociclib"},30: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1873916","display":"Ribociclib"}}",
chemo_dose,,No,No,Medication Administration,text,Chemotherapy dose,,,number,,,RECOMMENDED,[chemo_drug] <> '',MedicationAdministration,"["dosage"] = {"dose":chemo_dose}",,Code on chemo_units
chemo_units,,No,Yes,Medication Administration,dropdown,Chemotherapy dose units,0; mg/m2 | 1; mg/kg | 2; mg,,,,,MANDATORY,[chemo_drug] <> '',MedicationAdministration,"["dosage"] = {"dose":chemo_dose}","{0:{"value":chemo_dose,"unit":"milligram per square meter","system":"http://unitsofmeasure.org","code":"mg/m2"},1:{"value":chemo_dose,"unit":"milligram per kilogram","system":"http://unitsofmeasure.org","code":"mg/kg"},2:{"value":chemo_dose,"unit":"milligram","system":"http://unitsofmeasure.org","code":"mg"}}",
chemo_dur,,No,Yes,Medication Administration,text,Duration of chemotherapy (weeks),,,integer,,,MANDATORY,[chemo_drug] <> '',MedicationAdministration,"["effectivePeriod"]","{"start":1970-01-01T00:00:00+00:00,end:"start"+chemo_dur}",effectivePeriod variable has anonymized dates. The duration is the difference in time between both dates.
neoadj,,Yes ([chemo_drug] > 13),Yes ([chemo_drug] > 13 AND [chemo_drug] < 31),Medication Administration,dropdown,Completed neoadjuvant treatment,0; not-done | 1; stopped | 2; completed | 3; unknown,,,,,MINIMAL,[chemo_drug] <> '' AND [chemo_drug] > 13,MedicationAdministration,"["status"]","{0: "not-done", 1: "stopped", 2: "completed", 3: "unknown"}",
neoadj_chemo,,Yes ([chemo_drug] <= 13),Yes ([chemo_drug] <= '13' AND [chemo_drug] >= '31'),Medication Administration,text,Completed neoadjuvant treatment (number of cycles),,,integer,,,"MINIMAL - If the drug is any of this list: Doxorubicin, Epirubicin, Doxorubicin liposomal, Paclitaxel, Nab paclitaxel, Docetaxel, Carboplatin, Cyclophosphamide, Eribulin, Methotrexate, Fluorouracil, Vinorelbine, Gemcitabine, Sacituzumab govitecán",[chemo_drug] <> '' AND [chemo_drug] <= 13,MedicationAdministration,"["dosage"]",,"Code on acc_dose_units. This section was tricky. Depending on the conditions, you can find in the FHIR JSON Files: acc_dose/neoadj_chemo, chemo_dose/neoadj_chemo"
acc_dose,,No,No,Medication Administration - Total dose,text,Accumulation dose of chemotherapy,,,number,,,RECOMMENDED,[chemo_drug] <> '',MedicationAdministration,"["dosage"]",,Code on acc_dose_units
acc_dose_units,,No,Yes ([acc_dose] <> ''),Medication Administration - Total dose,dropdown,Accumulation dose of chemotherapy units,0; mg/m2 | 1; mg/kg | 2; mg,,,,,MANDATORY,[chemo_drug] <> '',MedicationAdministration,"["dosage"]","{"rateRatio":"numerator":{0:{"value":acc_dose,"unit":"milligram per square meter","system":"http://unitsofmeasure.org","code":"mg/m2"},1:{"value":acc_dose,"unit":"milligram per kilogram","system":"http://unitsofmeasure.org","code":"mg/kg"},2:{"value":acc_dose,"unit":"milligram","system":"http://unitsofmeasure.org","code":"mg"}},"denominator":{"value":"neoadj_chemo","unit":"Chemotherapy cycle","system":"http://snomed.info/sct","code":"399042005"}}",
chemo_drug_2,,No,No,Medication Administration,dropdown,Additional hemotherapy agent (Neoadjuvant Systemic Treatment),0; Capecitabine | 1; Carboplatin | 2; Cyclophosphamide | 3; Docetaxel | 4; Doxorubicin | 5; Doxorubicin liposomal | 6; Epirubicin | 7; Eribulin | 8; Fluorouracil | 9; Gemcitabine | 10; Methotrexate | 11; Nab paclitaxel | 12; Paclitaxel | 13; Sacituzumab govitecán | 14; Vinorelbin | 15; Lapatinib | 16; Pertuzumab | 17; TDM1 | 18; Trastuzumab | 19; Trastuzumab deruxtecán | 20; Tucatinib | 21; Anastrozole | 22; Exemestane | 23; Letrozole | 24; Tamoxifem | 25; Atezolizumab | 26; Durvalumab | 27; Pembrolizumab | 28; Abemaciclib | 29; Palbociclib | 30; Ribociclib | 31; Abraxane | 32; Adriamycin | 33; Bevacizumab | 34; Taxotere | 35; Tremelimumab | 36; Xentuzumab,,,,,RECOMMENDED,[chemo_drug] <> '',MedicationAdministration,"medicationCodeableConcept":{"coding":chemo_drug_2}","{0: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"194000","display":"Capecitabine"},1: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"40048","display":"Carboplatin"},2: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"3002","display":"Cyclophosphamide"},3: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"72962","display":"Docetaxel"},4: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"3639","display":"Doxorubicin"},5: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"214525","display":"Doxorubicin liposomal"},6: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"3995","display":"Epirubicin"},7: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1045453","display":"Eribulin"},8: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"4492","display":"Fluorouracil"},9: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"12574","display":"Gemcitabine"},10: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"6851","display":"Methotrexate"},11: {"system":"http://snomed.info/sct","code":"426653008","display":"Nab paclitaxel"},12: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"56946","display":"Paclitaxel"},13: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"2360232","display":"Sacituzumab govitecan"},14: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"39541","display":"Vinorelbin"},15: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"480167","display":"Lapatinib"},16: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1298944","display":"Pertuzumab"},17: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1371041","display":"TDM1"},18: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"224905","display":"Trastuzumab"},19: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"2267582","display":"Trastuzumab deruxtecan"},20: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"2361285","display":"Tucatinib"},21: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"84857","display":"Anastrozole"},22: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"258494","display":"Exemestane"},23: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"72965","display":"Letrozole"},24: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"10324","display":"Tamoxifem"},25: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1792776","display":"Atezolizumab"},26: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1919503","display":"Durvalumab"},27: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1547545","display":"Pembrolizumab"},28: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1946825","display":"Abemaciclib"},29: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1601374","display":"Palbociclib"},30: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1873916","display":"Ribociclib"}}",
chemo_dose_2,,No,No,Medication Administration,text,Additional chemotherapy dose,,,number,,,RECOMMENDED,[chemo_drug_2] <> '',MedicationAdministration,"["dosage"] = {"dose":chemo_dose_2}",,Code on chemo_units_2
chemo_units_2,,No,Yes ([chemo_dose_2] <> ''),Medication Administration,dropdown,Additional chemotherapy dose units,0; mg/m2 | 1; mg/kg | 2; mg,,,,,MANDATORY,[chemo_drug_2] <> '',MedicationAdministration,"["dosage"] = {"dose":chemo_dose_2}","{0:{"value":chemo_dose_2,"unit":"milligram per square meter","system":"http://unitsofmeasure.org","code":"mg/m2"},1:{"value":chemo_dose_2,"unit":"milligram per kilogram","system":"http://unitsofmeasure.org","code":"mg/kg"},2:{"value":chemo_dose_2,"unit":"milligram","system":"http://unitsofmeasure.org","code":"mg"}}",
chemo_dur_2,,No,Yes ([chemo_drug_2] <> ''),Medication Administration,text,Duration of additional chemotherapy (weeks),,,integer,,,MANDATORY,[chemo_drug_2] <> '',MedicationAdministration,"["effectivePeriod"]","{"start":1970-01-01T00:00:00+00:00,end:"start"+chemo_dur_2}",effectivePeriod variable has anonymized dates. The duration is the difference in time between both dates.
neoadj_2,,Yes ([chemo_drug_2] > 13),Yes ([chemo_drug_2] > 13 AND [chemo_drug_2] < 31),Medication Administration,dropdown,Completed additional neoadjuvant treatment,0; not-done | 1; stopped | 2; completed | 3; unknown,,,,,MINIMAL,[chemo_drug_2] <> '' AND [chemo_drug_2] > 13,MedicationAdministration,"["status"]","{0: "not-done", 1: "stopped", 2: "completed", 3: "unknown"}",
neoadj_chemo_2,,Yes ([chemo_drug_2] <= 13),Yes ([chemo_drug_2] <= '13' AND [chemo_drug_2] >= '31'),Medication Administration,text,"{0:{"value":chemo_dose_3,"unit":"milligram per square meter","system":"http://unitsofmeasure.org","code":"mg/m2"},1:{"value":chemo_dose_3,"unit":"milligram per kilogram","system":"http://unitsofmeasure.org","code":"mg/kg"},2:{"value":chemo_dose_3,"unit":"milligram","system":"http://unitsofmeasure.org","code":"mg"}}",,,integer,,,"MINIMAL- If the drug is any of this list: Doxorubicin, Epirubicin, Doxorubicin liposomal, Paclitaxel, Nab paclitaxel, Docetaxel, Carboplatin, Cyclophosphamide, Eribulin, Methotrexate, Fluorouracil, Vinorelbine, Gemcitabine, Sacituzumab govitecán",[chemo_drug_2] <> '' AND [chemo_drug_2] <= 13,MedicationAdministration,"["dosage"]",,"Code on acc_dose_units_2. This section was tricky. Depending on the conditions, you can find in the FHIR JSON Files: acc_dose_2/neoadj_chemo_2, chemo_dose_2/neoadj_chemo_2"
acc_dose_2,,No,No,Medication Administration - Total dose,text,Accumulation dose of chemotherapy,,,number,,,RECOMMENDED,[chemo_drug_2] <> '',MedicationAdministration,"["dosage"]",,Code on acc_dose_units_2
acc_dose_units_2,,No,Yes ([acc_dose_2] <> ''),Medication Administration - Total dose,dropdown,Accumulation dose of chemotherapy units,0; mg/m2 | 1; mg/kg | 2; mg,,,,,MANDATORY,[chemo_drug_2] <> '',MedicationAdministration,"["dosage"]","{"rateRatio":"numerator":{0:{"value":acc_dose_2,"unit":"milligram per square meter","system":"http://unitsofmeasure.org","code":"mg/m2"},1:{"value":acc_dose_2,"unit":"milligram per kilogram","system":"http://unitsofmeasure.org","code":"mg/kg"},2:{"value":acc_dose_2,"unit":"milligram","system":"http://unitsofmeasure.org","code":"mg"}},"denominator":{"value":"neoadj_chemo_2","unit":"Chemotherapy cycle","system":"http://snomed.info/sct","code":"399042005"}}",
chemo_drug_3,,No,No,Medication Administration,dropdown,Second additional hemotherapy agent (Neoadjuvant Systemic Treatment),0; Capecitabine | 1; Carboplatin | 2; Cyclophosphamide | 3; Docetaxel | 4; Doxorubicin | 5; Doxorubicin liposomal | 6; Epirubicin | 7; Eribulin | 8; Fluorouracil | 9; Gemcitabine | 10; Methotrexate | 11; Nab paclitaxel | 12; Paclitaxel | 13; Sacituzumab govitecán | 14; Vinorelbin | 15; Lapatinib | 16; Pertuzumab | 17; TDM1 | 18; Trastuzumab | 19; Trastuzumab deruxtecán | 20; Tucatinib | 21; Anastrozole | 22; Exemestane | 23; Letrozole | 24; Tamoxifem | 25; Atezolizumab | 26; Durvalumab | 27; Pembrolizumab | 28; Abemaciclib | 29; Palbociclib | 30; Ribociclib | 31; Abraxane | 32; Adriamycin | 33; Bevacizumab | 34; Taxotere | 35; Tremelimumab | 36; Xentuzumab,,,,,RECOMMENDED,[chemo_drug_2] <> '',MedicationAdministration,"medicationCodeableConcept":{"coding":chemo_drug_3}","{0: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"194000","display":"Capecitabine"},1: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"40048","display":"Carboplatin"},2: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"3002","display":"Cyclophosphamide"},3: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"72962","display":"Docetaxel"},4: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"3639","display":"Doxorubicin"},5: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"214525","display":"Doxorubicin liposomal"},6: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"3995","display":"Epirubicin"},7: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1045453","display":"Eribulin"},8: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"4492","display":"Fluorouracil"},9: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"12574","display":"Gemcitabine"},10: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"6851","display":"Methotrexate"},11: {"system":"http://snomed.info/sct","code":"426653008","display":"Nab paclitaxel"},12: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"56946","display":"Paclitaxel"},13: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"2360232","display":"Sacituzumab govitecan"},14: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"39541","display":"Vinorelbin"},15: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"480167","display":"Lapatinib"},16: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1298944","display":"Pertuzumab"},17: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1371041","display":"TDM1"},18: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"224905","display":"Trastuzumab"},19: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"2267582","display":"Trastuzumab deruxtecan"},20: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"2361285","display":"Tucatinib"},21: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"84857","display":"Anastrozole"},22: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"258494","display":"Exemestane"},23: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"72965","display":"Letrozole"},24: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"10324","display":"Tamoxifem"},25: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1792776","display":"Atezolizumab"},26: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1919503","display":"Durvalumab"},27: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1547545","display":"Pembrolizumab"},28: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1946825","display":"Abemaciclib"},29: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1601374","display":"Palbociclib"},30: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1873916","display":"Ribociclib"}}",
chemo_dose_3,,No,No,Medication Administration,text,Second additional chemotherapy dose,,,number,,,RECOMMENDED,[chemo_drug_3] <> '',MedicationAdministration,"["dosage"] = {"dose":chemo_dose_3}",,Code on chemo_units_3
chemo_units_3,,No,Yes ([chemo_dose_3] <> ''),Medication Administration,dropdown,Second additional chemotherapy dose units,0; mg/m2 | 1; mg/kg | 2; mg,,,,,MANDATORY,[chemo_drug_3] <> '',MedicationAdministration,"["dosage"] = {"dose":chemo_dose_3}","{0:{"value":chemo_dose_3,"unit":"milligram per square meter","system":"http://unitsofmeasure.org","code":"mg/m2"},1:{"value":chemo_dose_3,"unit":"milligram per kilogram","system":"http://unitsofmeasure.org","code":"mg/kg"},2:{"value":chemo_dose_3,"unit":"milligram","system":"http://unitsofmeasure.org","code":"mg"}}",
chemo_dur_3,,No,Yes ([chemo_drug_3] <> ''),Medication Administration,text,Duration of second additional chemotherapy (weeks),,,integer,,,MANDATORY,[chemo_drug_3] <> '',MedicationAdministration,"["effectivePeriod"]","{"start":1970-01-01T00:00:00+00:00,end:"start"+chemo_dur_3}",effectivePeriod variable has anonymized dates. The duration is the difference in time between both dates.
neoadj_3,,Yes ([chemo_drug_3] > 13),Yes ([chemo_drug_3] > 13 AND [chemo_drug_3] < 31),Medication Administration,dropdown,Completed second additional neoadjuvant treatment,0; not-done | 1; stopped | 2; completed | 3; unknown,,,,,MINIMAL,[chemo_drug_3] <> '' AND [chemo_drug_3] > 13,MedicationAdministration,"["status"]","{0: "not-done", 1: "stopped", 2: "completed", 3: "unknown"}",
neoadj_chemo_3,,Yes ([chemo_drug_3] <= 13),Yes ([chemo_drug_3] <= '13' AND [chemo_drug_3] >= '31'),Medication Administration,text,Completed second additional neoadjuvant treatment (number of cycles),,,integer,,,"MINIMAL - If the drug is any of this list: Doxorubicin, Epirubicin, Doxorubicin liposomal, Paclitaxel, Nab paclitaxel, Docetaxel, Carboplatin, Cyclophosphamide, Eribulin, Methotrexate, Fluorouracil, Vinorelbine, Gemcitabine, Sacituzumab govitecán",[chemo_drug_3] <> '' AND [chemo_drug_3] <= 13,MedicationAdministration,"["dosage"]",,"Code on acc_dose_units_3. This section was tricky. Depending on the conditions, you can find in the FHIR JSON Files: acc_dose_3/neoadj_chemo_3, chemo_dose_3/neoadj_chemo_3"
acc_dose_3,,No,No,Medication Administration - Total dose,text,Accumulation dose of chemotherapy,,,number,,,RECOMMENDED,[chemo_drug_3] <> '',MedicationAdministration,"["dosage"]",,Code on acc_dose_units_3.
acc_dose_units_3,,No,Yes ([acc_dose_3] <> ''),Medication Administration - Total dose,dropdown,Accumulation dose of chemotherapy units,0; mg/m2 | 1; mg/kg | 2; mg,,,,,MANDATORY,[chemo_drug_3] <> '',MedicationAdministration,"["dosage"]","{"rateRatio":"numerator":{0:{"value":acc_dose_3,"unit":"milligram per square meter","system":"http://unitsofmeasure.org","code":"mg/m2"},1:{"value":acc_dose_3,"unit":"milligram per kilogram","system":"http://unitsofmeasure.org","code":"mg/kg"},2:{"value":acc_dose_3,"unit":"milligram","system":"http://unitsofmeasure.org","code":"mg"}},"denominator":{"value":"neoadj_chemo_3","unit":"Chemotherapy cycle","system":"http://snomed.info/sct","code":"399042005"}}",
chemo_drug_4,,No,No,Medication Administration,dropdown,Third additional hemotherapy agent (Neoadjuvant Systemic Treatment),0; Capecitabine | 1; Carboplatin | 2; Cyclophosphamide | 3; Docetaxel | 4; Doxorubicin | 5; Doxorubicin liposomal | 6; Epirubicin | 7; Eribulin | 8; Fluorouracil | 9; Gemcitabine | 10; Methotrexate | 11; Nab paclitaxel | 12; Paclitaxel | 13; Sacituzumab govitecán | 14; Vinorelbin | 15; Lapatinib | 16; Pertuzumab | 17; TDM1 | 18; Trastuzumab | 19; Trastuzumab deruxtecán | 20; Tucatinib | 21; Anastrozole | 22; Exemestane | 23; Letrozole | 24; Tamoxifem | 25; Atezolizumab | 26; Durvalumab | 27; Pembrolizumab | 28; Abemaciclib | 29; Palbociclib | 30; Ribociclib | 31; Abraxane | 32; Adriamycin | 33; Bevacizumab | 34; Taxotere | 35; Tremelimumab | 36; Xentuzumab,,,,,RECOMMENDED,[chemo_drug_3] <> '',MedicationAdministration,"medicationCodeableConcept":{"coding":chemo_drug_4}","{0: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"194000","display":"Capecitabine"},1: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"40048","display":"Carboplatin"},2: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"3002","display":"Cyclophosphamide"},3: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"72962","display":"Docetaxel"},4: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"3639","display":"Doxorubicin"},5: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"214525","display":"Doxorubicin liposomal"},6: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"3995","display":"Epirubicin"},7: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1045453","display":"Eribulin"},8: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"4492","display":"Fluorouracil"},9: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"12574","display":"Gemcitabine"},10: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"6851","display":"Methotrexate"},11: {"system":"http://snomed.info/sct","code":"426653008","display":"Nab paclitaxel"},12: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"56946","display":"Paclitaxel"},13: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"2360232","display":"Sacituzumab govitecan"},14: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"39541","display":"Vinorelbin"},15: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"480167","display":"Lapatinib"},16: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1298944","display":"Pertuzumab"},17: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1371041","display":"TDM1"},18: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"224905","display":"Trastuzumab"},19: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"2267582","display":"Trastuzumab deruxtecan"},20: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"2361285","display":"Tucatinib"},21: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"84857","display":"Anastrozole"},22: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"258494","display":"Exemestane"},23: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"72965","display":"Letrozole"},24: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"10324","display":"Tamoxifem"},25: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1792776","display":"Atezolizumab"},26: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1919503","display":"Durvalumab"},27: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1547545","display":"Pembrolizumab"},28: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1946825","display":"Abemaciclib"},29: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1601374","display":"Palbociclib"},30: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1873916","display":"Ribociclib"}}",
chemo_dose_4,,No,No,Medication Administration,text,Third additional chemotherapy dose,,,number,,,RECOMMENDED,[chemo_drug_4] <> '',MedicationAdministration,"["dosage"] = {"dose":chemo_dose_4}",,Code on chemo_units_4
chemo_units_4,,No,Yes ([chemo_dose_4] <> ''),Medication Administration,dropdown,Third additional chemotherapy dose units,0; mg/m2 | 1; mg/kg | 2; mg,,,,,MANDATORY,[chemo_drug_4] <> '',MedicationAdministration,"["dosage"] = {"dose":chemo_dose_4}","{0:{"value":chemo_dose_4,"unit":"milligram per square meter","system":"http://unitsofmeasure.org","code":"mg/m2"},1:{"value":chemo_dose_4,"unit":"milligram per kilogram","system":"http://unitsofmeasure.org","code":"mg/kg"},2:{"value":chemo_dose_4,"unit":"milligram","system":"http://unitsofmeasure.org","code":"mg"}}",
chemo_dur_4,,No,Yes ([chemo_drug_4] <> ''),Medication Administration,text,Duration of third additional chemotherapy (weeks),,,integer,,,MANDATORY,[chemo_drug_4] <> '',MedicationAdministration,"["effectivePeriod"]","{"start":1970-01-01T00:00:00+00:00,end:"start"+chemo_dur_4}",effectivePeriod variable has anonymized dates. The duration is the difference in time between both dates.
neoadj_4,,Yes ([chemo_drug_4] > 13),Yes ([chemo_drug_4] > 13 AND [chemo_drug_4] < 31),Medication Administration,dropdown,Completed third additional neoadjuvant treatment,0; not-done | 1; stopped | 2; completed | 3; unknown,,,,,MINIMAL,[chemo_drug_4] <> '' AND [chemo_drug_4] > 13,MedicationAdministration,"["status"]","{0: "not-done", 1: "stopped", 2: "completed", 3: "unknown"}",
neoadj_chemo_4,,Yes ([chemo_drug_4] <= 13),Yes ([chemo_drug_4] <= '13' AND [chemo_drug_4] >= '31'),Medication Administration,text,Completed third additional neoadjuvant treatment (number of cycles),,,integer,,,"MINIMAL - If the drug is any of this list: Doxorubicin, Epirubicin, Doxorubicin liposomal, Paclitaxel, Nab paclitaxel, Docetaxel, Carboplatin, Cyclophosphamide, Eribulin, Methotrexate, Fluorouracil, Vinorelbine, Gemcitabine, Sacituzumab govitecán",[chemo_drug_4] <> '' AND [chemo_drug_4] <= 13,MedicationAdministration,"["dosage"]",,"Code on acc_dose_units_4. This section was tricky. Depending on the conditions, you can find in the FHIR JSON Files: acc_dose_4/neoadj_chemo_4, chemo_dose_4/neoadj_chemo_4"
acc_dose_4,,No,No,Medication Administration - Total dose,text,Accumulation dose of chemotherapy,,,number,,,RECOMMENDED,[chemo_drug_4] <> '',MedicationAdministration,"["dosage"]",,Code on acc_dose_units_4
acc_dose_units_4,,No,Yes ([acc_dose_4] <> ''),Medication Administration - Total dose,dropdown,Accumulation dose of chemotherapy units,0; mg/m2 | 1; mg/kg | 2; mg,,,,,MANDATORY,[chemo_drug_4] <> '',MedicationAdministration,"["dosage"]","{"rateRatio":"numerator":{0:{"value":acc_dose_4,"unit":"milligram per square meter","system":"http://unitsofmeasure.org","code":"mg/m2"},1:{"value":acc_dose_4,"unit":"milligram per kilogram","system":"http://unitsofmeasure.org","code":"mg/kg"},2:{"value":acc_dose_4,"unit":"milligram","system":"http://unitsofmeasure.org","code":"mg"}},"denominator":{"value":"neoadj_chemo_4","unit":"Chemotherapy cycle","system":"http://snomed.info/sct","code":"399042005"}}",
chemo_drug_5,,No,No,Medication Administration,dropdown,Fourth additional hemotherapy agent (Neoadjuvant Systemic Treatment),0; Capecitabine | 1; Carboplatin | 2; Cyclophosphamide | 3; Docetaxel | 4; Doxorubicin | 5; Doxorubicin liposomal | 6; Epirubicin | 7; Eribulin | 8; Fluorouracil | 9; Gemcitabine | 10; Methotrexate | 11; Nab paclitaxel | 12; Paclitaxel | 13; Sacituzumab govitecán | 14; Vinorelbin | 15; Lapatinib | 16; Pertuzumab | 17; TDM1 | 18; Trastuzumab | 19; Trastuzumab deruxtecán | 20; Tucatinib | 21; Anastrozole | 22; Exemestane | 23; Letrozole | 24; Tamoxifem | 25; Atezolizumab | 26; Durvalumab | 27; Pembrolizumab | 28; Abemaciclib | 29; Palbociclib | 30; Ribociclib | 31; Abraxane | 32; Adriamycin | 33; Bevacizumab | 34; Taxotere | 35; Tremelimumab | 36; Xentuzumab,,,,,RECOMMENDED,[chemo_drug_4] <> '',MedicationAdministration,"medicationCodeableConcept":{"coding":chemo_drug_5}","{0: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"194000","display":"Capecitabine"},1: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"40048","display":"Carboplatin"},2: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"3002","display":"Cyclophosphamide"},3: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"72962","display":"Docetaxel"},4: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"3639","display":"Doxorubicin"},5: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"214525","display":"Doxorubicin liposomal"},6: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"3995","display":"Epirubicin"},7: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1045453","display":"Eribulin"},8: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"4492","display":"Fluorouracil"},9: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"12574","display":"Gemcitabine"},10: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"6851","display":"Methotrexate"},11: {"system":"http://snomed.info/sct","code":"426653008","display":"Nab paclitaxel"},12: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"56946","display":"Paclitaxel"},13: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"2360232","display":"Sacituzumab govitecan"},14: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"39541","display":"Vinorelbin"},15: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"480167","display":"Lapatinib"},16: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1298944","display":"Pertuzumab"},17: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1371041","display":"TDM1"},18: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"224905","display":"Trastuzumab"},19: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"2267582","display":"Trastuzumab deruxtecan"},20: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"2361285","display":"Tucatinib"},21: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"84857","display":"Anastrozole"},22: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"258494","display":"Exemestane"},23: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"72965","display":"Letrozole"},24: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"10324","display":"Tamoxifem"},25: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1792776","display":"Atezolizumab"},26: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1919503","display":"Durvalumab"},27: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1547545","display":"Pembrolizumab"},28: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1946825","display":"Abemaciclib"},29: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1601374","display":"Palbociclib"},30: {"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"1873916","display":"Ribociclib"}}",
chemo_dose_5,,No,No,Medication Administration,text,Fourth additional chemotherapy dose,,,number,,,RECOMMENDED,[chemo_drug_5] <> '',MedicationAdministration,"["dosage"] = {"dose":chemo_dose_5}",,Code on chemo_units_5
chemo_units_5,,No,Yes ([chemo_dose_5] <> ''),Medication Administration,dropdown,Fourth additional chemotherapy dose units,0; mg/m2 | 1; mg/kg | 2; mg,,,,,MANDATORY,[chemo_drug_5] <> '',MedicationAdministration,"["dosage"] = {"dose":chemo_dose_5}","{0:{"value":chemo_dose_5,"unit":"milligram per square meter","system":"http://unitsofmeasure.org","code":"mg/m2"},1:{"value":chemo_dose_5,"unit":"milligram per kilogram","system":"http://unitsofmeasure.org","code":"mg/kg"},2:{"value":chemo_dose_5,"unit":"milligram","system":"http://unitsofmeasure.org","code":"mg"}}",
chemo_dur_5,,No,Yes ([chemo_drug_5] <> ''),Medication Administration,text,Duration of fourth additional chemotherapy (weeks),,,integer,,,MANDATORY,[chemo_drug_5] <> '',MedicationAdministration,"["effectivePeriod"]","{"start":1970-01-01T00:00:00+00:00,end:"start"+chemo_dur_5}",effectivePeriod variable has anonymized dates. The duration is the difference in time between both dates.
neoadj_5,,Yes ([chemo_drug_5] > 13),Yes ([chemo_drug_5] > 13 AND [chemo_drug_5] < 31),Medication Administration,dropdown,Completed fourth additional neoadjuvant treatment,0; not-done | 1; stopped | 2; completed | 3; unknown,,,,,MINIMAL,[chemo_drug_5] <> '' AND [chemo_drug_5] > 13,MedicationAdministration,"["status"]","{0: "not-done", 1: "stopped", 2: "completed", 3: "unknown"}",
neoadj_chemo_5,,Yes ([chemo_drug_5] <= 13),Yes ([chemo_drug_5] <= '13' AND [chemo_drug_5] >= '31'),Medication Administration,text,Completed fourth additional neoadjuvant treatment (number of cycles),,,integer,,,"MINIMAL - If the drug is any of this list: Doxorubicin, Epirubicin, Doxorubicin liposomal, Paclitaxel, Nab paclitaxel, Docetaxel, Carboplatin, Cyclophosphamide, Eribulin, Methotrexate, Fluorouracil, Vinorelbine, Gemcitabine, Sacituzumab govitecán",[chemo_drug_5] <> '' AND [chemo_drug_5] <= 13,MedicationAdministration,"["dosage"]",,"Code on acc_dose_units_5. This section was tricky. Depending on the conditions, you can find in the FHIR JSON Files: acc_dose_5/neoadj_chemo_5, chemo_dose_5/neoadj_chemo_5"
acc_dose_5,,No,No,Medication Administration - Total dose,text,Accumulation dose of chemotherapy,,,number,,,RECOMMENDED,[chemo_drug_5] <> '',MedicationAdministration,"["dosage"]",,Code on acc_dose_units_5
acc_dose_units_5,,No,Yes ([acc_dose_5] <> ''),Medication Administration - Total dose,dropdown,Accumulation dose of chemotherapy units,0; mg/m2 | 1; mg/kg | 2; mg,,,,,MANDATORY,[chemo_drug_5] <> '',MedicationAdministration,"["dosage"]","{"rateRatio":"numerator":{0:{"value":acc_dose_5,"unit":"milligram per square meter","system":"http://unitsofmeasure.org","code":"mg/m2"},1:{"value":acc_dose_5,"unit":"milligram per kilogram","system":"http://unitsofmeasure.org","code":"mg/kg"},2:{"value":acc_dose_5,"unit":"milligram","system":"http://unitsofmeasure.org","code":"mg"}},"denominator":{"value":"neoadj_chemo_5","unit":"Chemotherapy cycle","system":"http://snomed.info/sct","code":"399042005"}}",
hcontrac,,No,No,Medication Administration - Hormonal Contraception,dropdown,Use of hormonal contraception,0; yes | 1; no | 2; unknown,2,,,,RECOMMENDED,,Observation,"{"system":"http://snomed.info/sct","code":"1237404009","display":"Uses hormone method of contraception (finding)"}","{0:{"system":"http://snomed.info/sct","code":"373066001","display":"Yes"},1:{"system":"http://snomed.info/sct","code":"260415000","display":"Not detected"},2:{"system":"http://snomed.info/sct","code":"261665006","display":"Unknown"}}",
hcontrac_dur,,No,No,Medication Administration - Hormonal Contraception,text,Duration of hormonal contraception (months),,,integer,,,RECOMMENDED,"[hcontrac] = "0",Observation,"["effectivePeriod"]","{"start":1970-01-01T00:00:00+00:00,end:"start"+hcontrac_dur}",effectivePeriod variable has anonymized dates. The duration is the difference in time between both dates.
brca1,,No,No,Diagnostic report,dropdown,Genetic testing BRCA1,0; positive | 1; negative | 2; unknown,,,,,RECOMMENDED,,Observation,"{"system":"http://snomed.info/sct","code":"405823003","display":"BRCA1 mutation carrier detection test (procedure)"}","{0:{"system":"http://snomed.info/sct","code":"412734009","display":"BRCA1 gene mutation positive (finding)"},1:{"system":"http://snomed.info/sct","code":"412736006","display":"BRCA1 gene mutation negative (finding)"},2:{"system":"http://snomed.info/sct","code":"261665006","display":"Unknown (qualifier value)"}}",
brca2,,No,No,Diagnostic report,dropdown,Genetic testing BRCA2,0; positive | 1; negative | 2; unknown,,,,,RECOMMENDED,,Observation,"{"system":"http://snomed.info/sct","code":"405826006","display":"BRCA2 mutation carrier detection test (procedure)"}","{0:{"system":"http://snomed.info/sct","code":"412738007","display":"BRCA2 gene mutation positive (finding)"},1:{"system":"http://snomed.info/sct","code":"412739004","display":"BRCA2 gene mutation negative (finding)"},2:{"system":"http://snomed.info/sct","code":"261665006","display":"Unknown (qualifier value)"}}",
palb2,,No,No,Diagnostic report,dropdown,Genetic testing PALB2,0; positive | 1; negative | 2; unknown,,,,,RECOMMENDED,,Observation,"{"system":"http://loinc.org","code":"100761-6","display":"PALB2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method"}","{0:{"system":"http://snomed.info/sct","code":"10828004","display":"Positive"},1:{"system":"http://snomed.info/sct","code":"260385009","display":"Negative"},2:{"system":"http://snomed.info/sct","code":"261665006","display":"Unknown"}}",
chek2,,No,No,Diagnostic report,dropdown,Genetic testing CHEK2,0; positive | 1; negative | 2; unknown,,,,,RECOMMENDED,,Observation,"{"system":"http://loinc.org","code":"89038-4","display":"CHEK2 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method"}","{0:{"system":"http://snomed.info/sct","code":"10828004","display":"Positive"},1:{"system":"http://snomed.info/sct","code":"260385009","display":"Negative"},2:{"system":"http://snomed.info/sct","code":"261665006","display":"Unknown"}}",
use_case_7_complete,,No,No,Form Status,dropdown,Complete?,0; Incomplete | 1; Unverified | 2; Complete,0,,,,,,,,,